Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Robin Zeng’s high-stakes bets—from quitting his first job to founding CATL—have reshaped the global EV battery market.

The Chinese drugmaker raised HK$9.74 billion, equivalent to US$1.25 billion, in net proceeds, making it one of Hong Kong's largest IPOs so far this year. The stock was priced at HK$44.05 per share, ...

Jiangsu Hengrui Pharmaceuticals, one of China’s largest drug makers, began trading on the Hong Kong stock exchange on Friday, ...

ONE of the assumed pressure points in the ongoing nonviolent dispute between the United States and China is the latter's ...

Backed by the likes of Tencent, HongShan and DST Global, Airwallex has reached a valuation of $6.2 billion following its ...

The Hong Kong University of Science and Technology (HKUST) today announced an open invitation to international undergraduate and postgraduate students currently enrolled at Harvard University, as well ...